ClinicalTrials.gg
RecruitingNCT07206628Updated Aug 17, 2026

Real-world Study to Assess Adherence to IOP Lowering Therapy in Patients With Glaucoma or Ocular Hypertension Using CONNECTDROP®

An observational study in Adherence to Glaucoma Therapy, sponsored by Laboratoires Thea. Recruiting at 15 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Laboratoires Thea · Observational

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 53 studies in Glaucoma with a site in Italy — 7 open to participants now, 8 under way, 1 of them phase 3. Glaucoma · Italy.

Planned enrollment
5th of 13
200 · median 200
Started
2025
with 3 others
Observational
13 of 53
6 open now
Registered
50th of 53
by date

Among the 53 studies in Glaucoma with a site in Italy, this one is the 5th largest by planned enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, and was the 50th registered.

Glaucoma

1,421 studies on the registry are indexed under Glaucoma; 221 are open to participants now.

Browse Glaucoma studies →

Open to participants now

7 of the 53 studies in Glaucoma with a site in Italy are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Glaucoma with a site in Italy, or all of them as a file.
02

Study summary

The goal of this real-life, national, multicentre, prospective clinical investigation is to describe the adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops using connected device CONNECTDROP®

The main questions it aims to answer are:

  • The mean annual adherence rate, defined as the percentage of the prescribed doses taken by the patient
  • The adherence profile of each patient
  • The association between the adherence profile, the objective adherence data and the clinical data.

Participants will use the connected device CONNECTDROP® associated with the smartphone application on a daily basis.

03

Conditions studied

  • Adherence to Glaucoma Therapy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Glaucoma or OHT patients from hospital and/or private practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (≥ 18 years old), man or woman
  • Patient with a diagnosis of bilateral open angle glaucoma or OHT
  • Patients being prescribed with glaucoma eye drops in EASYGRIP® bottle for at least 6 weeks in monotherapy.
  • Patient willing to participate in the study
  • Patient who consents for data collection in the frame of the study

Exclusion criteria

Exclusion Criteria:

  • Pregnant and/or lactating woman
  • Patient receiving another ocular treatment for a chronic condition (i.e. regular instillations for several months)
  • Protected patient: adult under guardianship, curatorship or other protection legal, deprived of liberty by judicial or administrative decision
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group receiving T9060 CONNECTDROP
06

What researchers measure

Primary outcomes

  1. Adherence rate over time in patients with glaucoma or OHT already treated with IOP-lowering eye drops in EASYGRIP® bottle clipped with CONNECTDROP®

    Assessment of the mean annual adherence rate, defined as the percentage of the prescribed doses actually taken by the patient (i.e. at least 2 instillations per day).

    Time frame: From enrollment to the end of the study at 12 months

07

Study locations

14 of 15 sites recruiting
  • Studio Oculistico D'Azeglio
    Bologna, 40100, Italy
    Recruiting
    • Gian Luca Laffi · Principal investigator
  • Centro Medico Polispecialistico Di Maita
    Catania, Italy
    Recruiting
    • Marco Di Maita · Principal investigator
  • Studio Medico Oculistico Dr.ssa Rosa SCHIAVELLI s.r.l.
    Corigliano, Italy
    Recruiting
    • Ester Elmo · Principal investigator
  • Ospedale Policlinico S. Martino-IRCCS Clinica Oculistica Università di Genova
    Genova, 16132, Italy
    Recruiting
    • Michele Iester · Principal investigator
  • Centro Corporis Lab
    Lecce, 73100, Italy
    Recruiting
    • Gianluca Besozzi · Principal investigator
  • Studi Oculistici - Dott. Andrea Bedei
    Lucca, 55047, Italy
    Recruiting
    • Andrea Bedei · Principal investigator
  • Poliambulatorio Chirurgico Modenese Eyecare Clinic
    Modena, Italy
    Recruiting
    • Enrico Martini · Principal investigator
  • Centro Oculistico Ramovecchi S.r.l.
    Morrovalle, 62010, Italy
    Recruiting
    • Vincenzo Ramovecchi · Principal investigator
  • Dipartimento di Neuroscienze e Scienze Riproduttive ed Odontostomatologiche, Università degli studi di Napoli Federico II
    Naples, Italy
    Recruiting
    • Ciro Costagliola · Principal investigator
  • UOSD di Oculistica, Fondazione PTV Policlinico Tor Vergata
    Roma, 00133, Italy
    Recruiting
    • Carlo Nucci · Principal investigator
  • Ambulatorio Oculistica Ospedale San Carlo di Nancy -GVM-
    Roma, 00165, Italy
    Not yet recruiting
    • Marco Brinelli · Principal investigator
  • IRCCS Fondazione G.B. Bietti
    Roma, 00184, Italy
    Recruiting
    • Francesco Oddone · Principal investigator
  • Ospedale San Donà Piave, Aussl 4 Veneto Orientale, UOC Oculistica
    San Donà di Piave, Italy
    Recruiting
    • Francesco Giuseppe Stefanon · Principal investigator
  • AOU Sassari Clinica Oculistica
    Sassari, 07100, Italy
    Recruiting
    • Matteo Sacchi · Principal investigator
  • Humanitas Gradenigo U.O. Oculistica
    Torino, 10153, Italy
    Recruiting
    • Teresa Rolle · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2027, 24 months after the start.

Of 135 observational studies under Glaucoma, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 208. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2025
First posted
Oct 3, 2025
StartActual
Sep 19, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2027
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07206628
Lead sponsor
Laboratoires Thea
Responsible party
Sponsor
First posted
Oct 3, 2025
Start date
Sep 19, 2025
Primary completion
Sep 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 17, 2026

Study contacts

Medical Operation Manager
Contact
Fabienne.HESKIA@theapharma.com
+33 4 73 98 14 36

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion